Calidi Biotherapeutics provides corporate update; debt reduced by $3.1M, IND planned for Q4 2026

Calidi Biotherapeutics, Inc.

Term debt and notes payable reduced to $0.7M at Dec 31, 2025, from $3.8M at Dec 31, 2024 (unaudited).
G&A expenses cut by $2.3M in first nine months of 2025 vs same period 2024.
Plans to file IND for CLD-401 in Q4 2026 targeting NSCLC, triple-negative breast, and head/neck cancer.
Expects proof-of-concept data for RedTail platform in non-oncology indications and BiTE delivery with T-cell amplifiers.
New CEO Eric Poma, PhD (appointed 2025) and CMO Guy Travis Clifton, MD bring biopharma experience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.